Mayo Clinic is the first facility approved to manufacture Choline C 11 Injection
September 18, 2012 (Washington, D.C.) -- The U.S. Food and Drug Administration has approved the production and use of Choline C 11 Injection, a Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.
Choline C 11 Injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer.
Recent comments